Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care
Brief Summary
Condition or Disease
- Depression
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Recruiting |
| Study results: | No Results Available |
| Age: | 18 Years and older (Adult, Older Adult) |
| Enrollment: | 80 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Sep 08, 2016 | |
|---|---|---|
| Primary Completion: | Sep 19, 2020 | |
| Completion Date: | Sep 19, 2020 | |
| Study First Posted: | May 26, 2016 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Dec 11, 2018 |
Sponsors / Collaborators
Ketamine, a molecule mainly used as an analgesic in palliative care, turns out to be an excellent fast acting antidepressant. By acting as an NMDA receptor antagonist, its mechanism of action is complementary to classical and long acting antidepressants like Selective Serotonin Reuptake Inhibitors (SSRI). In particular, ketamine is able to boost synaptogenesis in only a few hours whereas long-term prescription of SSRI can stimulate neurogenesis.
The purpose of this study is to evaluate a new therapeutic strategy that could integrate ketamine in the same time than SSRI, to control depression symptoms faster and optimize patient's quality of life complementary to treatments of cancer.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
More Details
| NCT Number: | NCT02783430 |
|---|---|
| Acronym: | KETAPAL |
| Other IDs: | 2014_22|2014-004361-24|PHRCI_2013 |
| Study URL: | https://ClinicalTrials.gov/show/NCT02783430 |